New virus therapy targets Hard-to-Treat cancers in first human trial
Disease control
Recruiting now
This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with another drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals a…
Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC